Explore baxter.com

This site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative.

Renal Care EMEA

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Modern PD

    Modern PD offers patients many choices. Are you ready to voice them?

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx

    Innovative Expanded Hemodialysis (HDx) therapy is the next evolution in hemodialysis treatment.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Clinical Data

Clinical research lies at the heart of who we are. Baxter uses scientific evidence systematically, and transparently, to inform the development of new and state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Baxter. 

A Focus on Clinical Research

HDx

Could symptom burden predict subsequent healthcare use in patients with end stage kidney disease on hemodialysis care

View resource
HDx

Transforming Participation in Chronic Kidney Disease

View resource
HDx

Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial.

View resource
HDx

Classification of Uremic Toxins and Their Role in Kidney Failure: An Expert Consensus Conference

View resource
HDx

Comparison of expanded hemodialysis using a medium cut-off dialyzer versus hemodiafiltration: an observational prospective study

View resource
HDx

Distribution of peripheral blood t cell subtypes in hemodialysis patients treated with medium cut-off membranes and high-flux membranes

View resource
HDx

Effectiveness of medium cut-off vs high flux dialyzers: a propensity score matching cohort study

View resource
HDx

Effects of different dialysis techniques on inflammation in maintenance hemodialysis patients with covid-19: a randomized study

View resource
HDx

Efficacy of expanded hemodialysis at different dialysate flows

View resource
HDx

Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins

View resource
HDx

Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial

View resource
HDx

Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial.

View resource

Are you interested in additional information about ways in which we are transforming Renal Care through Patient-Centric Innovations?

Request information here

About Us
Baxter has been a front-runner in the treatment and management of end-stage kidney disease for over 85 years. Today, our state-of-the-art solutions for both hemodialysis and peritoneal dialysis are transforming global renal care. It’s why you can rely on us to be the type of dedicated partner who understands the challenges you face throughout the continuum of care to meet the individual needs of your patients.
 

Baxter, AK 98, AN69, Artis Physio Plus, BiCart, CWP 800, Evodial, Homechoice, Nephral ST, Novaline, Polyflux, Revaclear, Sharesource, Sharesource Adequest, SoftPac, SelectBag, Theralite and Theranova are trademarks of Baxter International Inc. or its subsidiaries.

©Copyright 2024 Baxter. All rights reserved.